PFE · Pfizer, Inc.
$27.72
+0.25% last session
End-of-day data · close of 2026-09-11
Market cap
$158B
Enterprise value
$210B
Trailing P/E
36.4
Forward P/E
9.6
Dividend yield
6.0%
Beta
0.30
Avg volume
42M
Employees
75K
Daily Change %
0.25%
5 Days Change
-2.36%
10 Days Change
-2.39%
30 Days Change
4.36%
60 Days Change
16.95%
Month to Day Change
-2.70%
Year to Day Change
17.32%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — PFE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-10
Latest call per bank · past 12 months
HSBC
Hold$30.00
+8.5% vs priceBank of America
Neutral$26.00
-6.0% vs priceJP Morgan
Neutral$28.00
+1.3% vs priceRBC Capital
Sector Perform$25.00
-9.6% vs priceCitigroup
Neutral$27.00
-2.4% vs priceUBS
Neutral$27.00
-2.4% vs priceMorgan Stanley
Equal-Weight$28.00
+1.3% vs priceBarclays
Underweight$25.00
-9.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | HSBC | Maintains | Hold | $28.00 → $30.00 |
| 2026-08-07 | Guggenheim | Maintains | Buy | $35.00 → $31.00 |
| 2026-07-13 | BMO Capital | Maintains | Outperform | $34.00 → $30.00 |
| 2026-07-13 | Guggenheim | Maintains | Buy | $36.00 → $35.00 |
| 2026-07-10 | Bank of America | Maintains | Neutral | $27.00 → $26.00 |
| 2026-07-08 | JP Morgan | Maintains | Neutral | $30.00 → $28.00 |
| 2026-07-06 | Cantor Fitzgerald | Reiterates | Neutral | $27.00 |
| 2026-07-06 | HSBC | Downgrade | Buy → Hold | $32.00 → $28.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.0% above the 50-day MA ($26.14).
- Price vs 200-day MA: Trading 8.6% above the 200-day MA ($25.53).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.19) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($29.02).
PFE Price Chart
Loading chart for PFE…
Fundamentals
About Pfizer, Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.